Genome-Wide Association Study Identifies Novel Restless Legs Syndrome Susceptibility Loci on 2p14 and 16q12.1 by Winkelmann, Juliane et al.
Genome-Wide Association Study Identifies Novel
Restless Legs Syndrome Susceptibility Loci on 2p14 and
16q12.1
Juliane Winkelmann1,2,3*, Darina Czamara4., Barbara Schormair1,3., Franziska Knauf1,3, Eva C. Schulte2,
Claudia Trenkwalder5, Yves Dauvilliers6, Olli Polo7,8, Birgit Ho¨gl9, Klaus Berger10, Andrea Fuhs10, Nadine
Gross2, Karin Stiasny-Kolster11,12, Wolfgang Oertel12, Cornelius G. Bachmann13, Walter Paulus13, Lan
Xiong14, Jacques Montplaisir15,16, Guy A. Rouleau14, Ingo Fietze17, Jana Va´vrova´18, David Kemlink18,
Karel Sonka18, Sona Nevsimalova18, Siong-Chi Lin19, Zbigniew Wszolek19, Carles Vilarin˜o-Gu¨ell19,
Matthew J. Farrer19, Viola Gschliesser9, Birgit Frauscher9, Tina Falkenstetter9, Werner Poewe9, Richard P.
Allen20, Christopher J. Earley20, William G. Ondo21, Wei-Dong Le21, Derek Spieler1,3, Maria Kaffe2,3,
Alexander Zimprich22, Johannes Kettunen23,24, Markus Perola23,24, Kaisa Silander23,24, Isabelle Cournu-
Rebeix25,26,27, Marcella Francavilla25,26,27, Claire Fontenille25,26,27, Bertrand Fontaine25,26,27, Pavel
Vodicka28, Holger Prokisch1,3, Peter Lichtner1,3, Paul Peppard29, Juliette Faraco30, Emmanuel Mignot30,
Christian Gieger31, Thomas Illig32, H.-Erich Wichmann33,34,35, Bertram Mu¨ller-Myhsok4, Thomas
Meitinger1,3
1 Institute of Human Genetics, Technische Universita¨t Mu¨nchen, Munich, Germany, 2Department of Neurology, Technische Universita¨t Mu¨nchen, Munich, Germany,
3 Institute of Human Genetics, Helmholtz Zentrum Mu¨nchen – German Research Center for Environmental Health, Neuherberg, Germany, 4Max Planck Institute of
Psychiatry, Munich, Germany, 5 Paracelsus-Elena-Hospital, Kassel, Germany, 6Unite´ du Sommeil, Service de Neurologie, Hoˆpital Gui-de-Chauliac, INSERM U1061,
Montpellier, France, 7Department of Pulmonary Medicine, Tampere University Hospital, Tampere, Finland, 8 Sleep Research Unit, University of Turku, Turku, Finland,
9Department of Neurology, Innsbruck Medical University, Innsbruck, Austria, 10 Institute of Epidemiology and Social Medicine, University Mu¨nster, Mu¨nster, Germany,
11 Somnomar, Sleep Research Institute, Marburg, Germany, 12Department of Neurology, Center of Nervous Diseases, Philipps University, Marburg, Germany,
13Department of Clinical Neurophysiology, University of Go¨ttingen, Go¨ttingen, Germany, 14Centre of Excellence in Neuromics, CHUM Research Centre and the
Department of Medicine, University of Montreal, Montreal, Canada, 15 Laboratoire d’e´tude des maladies du cerveau, Centre de recherche du CHUM, Hoˆpital Notre-Dame,
Universite´ de Montre´al, Montre´al, Canada, 16Centre d’e´tude du sommeil, Hoˆpital du Sacre´-Coeur de Montre´al, Montre´al, Canada, 17Charite – Universita¨tsmedizin Berlin
Interdisciplinary Center of Sleep Medicine, Berlin, Germany, 18Department of Neurology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 19Centre
for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada, 20Department of Neurology, Johns Hopkins University, Baltimore, Maryland,
United States of America, 21Department of Neurology, Baylor College of Medicine, Houston, Texas, United States of America, 22Department of Neurology, Medical
University of Vienna, Vienna, Austria, 23 Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, 24Department of Chronic Disease
Prevention, National Institute for Health and Welfare, Helsinki, Finland, 25 INSERM, UMR_S975, Paris, France, 26Centre de Recherche Institut du Cerveau et de la Moelle,
CNRS 7225, Paris, France, 27 Fe´de´ration des maladies du syste`me nerveux, Pitie´ – Salpeˆtrie`re Hospital, AP-HP, Paris, France, 28 Institute of Experimental Medicine, Czech
Academy of Sciences, Prague, Czech Republic, 29Department of Population Health Sciences, University of Wisconsin, Madison, Wisconsin, United States of America,
30Center For Narcolepsy, Stanford University, Palo Alto, California, United States of America, 31 Institute of Genetic Epidemiology, Helmholtz Zentrum Mu¨nchen –
German Research Center for Environmental Health, Neuherberg, Germany, 32Unit for Molecular Epidemiology, Helmholtz Zentrum Mu¨nchen – German Research Center
for Environmental Health, Neuherberg, Germany, 33 Institute of Epidemiology I, Helmholtz Zentrum Mu¨nchen – German Research Center for Environmental Health,
Neuherberg, Germany, 34 Institute of Medical Informatics, Biometry, and Epidemiology, Chair of Epidemiology, Ludwig-Maximilians-Universita¨t, Munich, Germany,
35 Klinikum Grosshadern, Munich, Germany
Abstract
Restless legs syndrome (RLS) is a sensorimotor disorder with an age-dependent prevalence of up to 10% in the general
population above 65 years of age. Affected individuals suffer from uncomfortable sensations and an urge to move in the
lower limbs that occurs mainly in resting situations during the evening or at night. Moving the legs or walking leads to an
improvement of symptoms. Concomitantly, patients report sleep disturbances with consequences such as reduced daytime
functioning. We conducted a genome-wide association study (GWA) for RLS in 922 cases and 1,526 controls (using 301,406
SNPs) followed by a replication of 76 candidate SNPs in 3,935 cases and 5,754 controls, all of European ancestry. Herein, we
identified six RLS susceptibility loci of genome-wide significance, two of them novel: an intergenic region on chromosome
2p14 (rs6747972, P = 9.036 10211, OR = 1.23) and a locus on 16q12.1 (rs3104767, P = 9.46 10219, OR = 1.35) in a linkage
disequilibrium block of 140 kb containing the 59-end of TOX3 and the adjacent non-coding RNA BC034767.
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Introduction
Restless legs syndrome (RLS) is a common neurological disorder
with a prevalence of up to 10%, which increases with age [1]. Affected
individuals suffer from an urge to move due to uncomfortable
sensations in the lower limbs present in the evening or at night. The
symptoms occur during rest and relaxation, with walking or moving
the extremity leading to prompt relief. Consequently, initiation and
maintenance of sleep become defective [1]. RLS has been associated
with iron deficiency, and is pharmacologically responsive to dopami-
nergic substitution. Increased cardiovascular events, depression, and
anxiety count among the known co-morbidities [1].
Genome-wide association studies (GWAs) identified genetic risk
factors within MEIS1, BTBD9, PTPRD, and a locus encompassing
MAP2K5 and SKOR1 [2–4]. To identify additional RLS suscep-
tibility loci, we undertook an enlarged GWA in a German case-
control population, followed by replication in independent case-
control samples originating from Europe, the United States of
America, and Canada. In doing so, we identified six RLS
susceptibility loci with genome-wide significance in the joint
analysis, two of them novel: an intergenic region on chromosome
2p14 and a locus on 16q12.1 in close proximity to TOX3 and the
adjacent non-coding RNA BC034767.
Results/Discussion
We enlarged our previously reported [2,4] GWA sample to 954
German RLS cases and 1,814 German population-based controls
from the KORA-S3/F3 survey and genotyped them on Affymetrix
5.0 (cases) and 6.0 (controls) arrays. To correct for population
stratification, as a first step, we performed a multidimensional
scaling (MDS) analysis, leading to the exclusion of 18 controls as
outliers. In a second step, we conducted a variance components
analysis to identify any residual substructure in the remaining
samples, resulting in an inflation factor l of 1.025 (Figures S1 and
S2). The first four axes of variation from the MDS analysis were
included as covariates in the association analysis of the genome-
wide stage and all P-values were corrected for the observed l.
Prior to statistical analysis, genotyping data was subjected to
extensive quality control. We excluded a total of 302 DNA samples
due to a genotyping call rate ,98 %. For individual SNP quality
control, we adopted a stringent protocol in order to account for
the complexity of an analysis combining 5.0 and 6.0 arrays. We
excluded SNPs with a minor allele frequency (MAF) ,5%, a
callrate ,98%, or a significant deviation from Hardy-Weinberg
Equilibrium (HWE) in controls (P,0.00001). In addition, we
dropped SNPs likely to be false-positive associations due to
differential clustering between 5.0 and 6.0 arrays by adding a
second set of cases of an unrelated phenotype and discarding SNPs
showing association in this setup (see Materials and Methods).
Finally, we tested 301,406 SNPs for association in 922 cases and
1,526 controls. Based on a threshold level of a nominal l-corrected
PGWA,10
-4, a total of 47 SNPs distributed over 26 loci were
selected for follow-up in the replication study (Figure 1, Table S1).
We genotyped these 47 SNPs together with 29 adjacent SNPs in
strong linkage disequilibrium (LD, r2=0.5–0.9) using the Sequenom
iPLEX platform in seven case-control populations of European
descent, comprising a total of 3,935 cases and 5,754 controls. Eleven
SNPs with a call rate,95%,MAF,5%, and P,0.00001 for deviation
from HWE in controls as well as 432 samples with a genotyping call
rate,90%were excluded. A set of 47 SNPs, genotyped in 186 samples
on both platforms (Affymetrix and Sequenom), was used to calculate an
average concordance rate of 99.24 %.
The combined analysis of all replication samples confirmed the
known four susceptibility loci and, in addition, identified two novel
association signals on chromosomes 2p14 and 16q12.1 (Table 1).
To address possible population stratification within the combined
replication sample, we performed a fixed-effects meta-analysis. For
four of the replication case-control populations, we included l
inflation factors which were available from a genomic controls
experiment in a previous study in these populations [4]. These
were used to correct the estimates for the standard error. Joint
analysis of GWA and all replication samples showed genome-wide
significance for these two novel loci as well as for the known RLS
loci in MEIS1, BTBD9, PTPRD, and MAP2K5/SKOR1 with a
nominal l -corrected PJOINT ,5610
28 (Table 1). Depending on
the variable power to detect the effects, the separate analyses of
individual subsamples in the replication either confirmed the
association after correction for multiple testing or yielded
nominally significant results (Tables S2 and S3). The differing
relevance of the risk loci in the individual samples is illustrated in
Novel Restless Legs Syndrome Susceptibility Loci
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forest plots (Figure 2). There was no evidence of epistasis between
any of the six risk loci (PBonferroni .0.45).
The association signal on 2p14 (rs6747972: nominal l-corrected
PJOINT = 9.03610
211, odds ratio (OR) = 1.23) is located in an LD
block of 120 kb within an intergenic region 1.3 Mb downstream of
MEIS1 (Figure 3). Assuming a long-range regulatory function of
the SNP-containing region, in silico analysis for clusters of highly
conserved non-coding elements using the ANCORA browser
(http://ancora.genereg.net) identified MEIS1 as well as ETAA1 as
potential target genes [5,6].
The second locus on chromosome 16q12.1 (rs3104767: nominal
l-corrected PJOINT = 9.4610
219, OR=1.35) is located within an
LD block of 140 kb (Figure 3), which contains the 59UTR of
TOX3 (synonyms TNRC9 and CAGF9) and the non-coding RNA
BC034767 (synonym LOC643714). TOX3 is a member of the high
mobility box group family of non-histone chromatin proteins
which interacts with CREB and CBP and plays a critical role in
mediating calcium-dependent transcription in neurons [7]. GWAs
have identified susceptibility variants for breast cancer in the
identical region [8]. The best-associated breast cancer SNP,
rs3803662, is in low LD (r2,0.1, HapMap CEU data) with
rs3104767, but showed association to RLS (l-corrected nominal
PGWA= 7.29610
27). However, logistic regression analysis condi-
tioned on rs3104767 demonstrated that this association is
dependent on rs3104767 (rs3803662: PGWA/conditioned = 0.2883).
BC034767 is represented in GenBank by two identical mRNA
transcripts, BC034767 and BC029912. According to the gene
model information of the UCSC and Ensembl genome browsers
(http://genome.ucsc.edu and http://www.ensembl.org/index.
html), these mRNAs are predicted to be non-coding. Additional
in silico analysis using the Coding Potential Calculator (http://cpc.
cbi.pku.edu.cn) supported this by attributing only a weak coding
potential to this RNA, suggesting a regulatory function instead [9].
We also searched for rare alleles with strong effects and performed
a mutation screening by sequencing all coding and non-coding
Figure 1. Manhattan plot of the GWA. Association results of the GWA stage. The x-axis represents genomic position along the 22 autosomes and
the x-chromosome, the y-axis shows -log10(P) for each SNP assayed. SNPs with a nominal l-corrected P,1024 are highlighted as circles.
doi:10.1371/journal.pgen.1002171.g001
Author Summary
Restless legs syndrome (RLS) is one of the most common
neurological disorders. Patients with RLS suffer from an urge to
move the legs and unpleasant sensations located mostly deep
in the calf. Symptoms mainly occur in resting situations in the
evening or at night. As a consequence, initiation and
maintenance of sleep become defective. Here, we performed
a genome-wide association study to identify common genetic
variants increasing the risk for disease. The genome-wide
phase included 922 cases and 1,526 controls, and candidate
SNPs were replicated in 3,935 cases and 5,754 controls, all of
European ancestry. We identified two new RLS–associated loci:
an intergenic region on chromosome 2p14 and a locus on
16q12.1 in a linkage disequilibrium block containing the 59-
end of TOX3 and the adjacent non-coding RNA BC034767.
TOX3 has been implicated in the development of breast
cancer. The physiologic role of TOX3 and BC034767 in the
central nervous system and a possible involvement of these
two genes in RLS pathogenesis remain to be established.
Novel Restless Legs Syndrome Susceptibility Loci
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exons of TOX3 and BC034767 in 188 German RLS cases (Table
S4). In TOX3, a total of nine variants not listed in dbSNP (Build
130) were found, three of which are non-synonymous. Only one of
these is also annotated in the 1000 Genomes project (November
2010 data release). Three additional new variants were located in
putative exons 1 and 2 of BC034767. Analysis of the frequency of
these variants as well as all known non-synonymous, frameshift,
and splice-site coding SNPs in TOX3 in a subset of one of the
replication samples (726 cases and 735 controls from the GER1
sample) did not reveal any association to RLS. For a power of
.80%, however, variants with an OR above 4.5 and a MAF
$0.01 would be required. For even lower MAFs, ORs $10 would
be necessary for sufficient power. Furthermore, the described
CAG repeat within exon 7 of TOX3 was not polymorphic as
shown by fragment analysis in 100 population-based controls.
According to publicly available expression data (http://genome.
ucsc.edu), in humans, BC034767 is expressed in the testes only,
while TOX3 expression has been shown in the salivary glands, the
trachea, and in the CNS. Detailed in-depth real time PCR
profiling of TOX3 showed high expression levels in the frontal and
occipital cortex, the cerebellum, and the retina [10]. To assess a
putative eQTL function of rs6747972 or rs3104767, we studied
the SNP-genotype-dependent expression of TOX3 and BC034767
as well as of genes known to directly interact with TOX3 (CREB-1/
CREBBP/CITED1) and potential target genes of long-range
regulatory elements at the locus on chromosome 2 (MEIS1/
ETAA1) in RNA expression microarray data from peripheral
blood in 323 general population controls [11]. No differential
genotype-dependent expression variation was found.
To assess the potential for genetic risk prediction, we split our
GWA sample in a training and a test set and determined classifiers
for case-control status in the training set to predict case-control
status in the test set. Training and test set were independent of
each other – not only with respect to included individuals but also
with respect to the genotyping procedure as we used genotypes
generated on different genotyping platforms. As training set, we
used those cases of the current GWA which had been genotyped
on 500K arrays in a previous GWA and the corresponding control
set [2], in total, 326 cases and 1,498 controls. The test set
comprised 583 cases and 1,526 controls, genotyped on 5.0/6.0
arrays as part of the current study. Prior to the analysis, we
removed the six known risk loci and performed LD-pruning to
limit the analysis to SNPs not in LD with each other. In the end, a
total of 76,532 SNPs were included in the pruned dataset. We
conducted logistic regression with age and sex as covariates. Based
on these association results, the sum score of SNPs showing the
most significant effects (i.e. the number of risk alleles over all SNPs)
weighted by the ln(OR) of these effects was chosen as predictor
variable in the test set. We then varied the P-value threshold for
SNPs included in the sum score. For a P-value ,0.6, we observed
a maximum area under the curve (AUC) of 63.9% and an
explained genetic variance of 6.6% (Nagelkerke’s R), values
comparable to estimates obtained for other complex diseases such
as breast cancer or diabetes (Table S5) [12–14]. Inclusion of the six
known risk loci in this analysis resulted in a maximum AUC of
64.2% and an explained genetic variance of 6.8%.
Additionally, we performed risk prediction in the combined
GWA and replication sample including only the six established
RLS risk loci. For this purpose, we used the weighted risk allele
score resulting in ORs of up to 8.6 (95% CI: 2.46–46.25) and an
AUC of 65.1% (Figures S3 and S4).
By increasing the size of our discovery sample, we have
identified two new RLS susceptibility loci. The top six loci show
effect sizes between 1.22 and 1.77 and risk allele frequencies
between 19 and 82%, and reveal genes in neuronal transcription
pathways not previously suspected to be involved in the disorder.
Materials and Methods
Study population and phenotype assessment
Ethics statement. Written informed consent was obtained
from each participant in the respective language. The study has
Table 1. Association results of GWA and joint analysis of GWA and replication.
Chr Locus LD block (Mb) SNP Position (bp)
Risk
allele
Risk allele
frequency
cases/controls PGWA PREPLICATION PJOINT
Odds ratio
(95% CI)
Known risk loci (1 SNP per locus)
2 MEIS1 66.57–66.64 rs2300478 66634957 G 0.35/0.24 7.77610216 4.39610235 3.40610249 1.68 (1.57–1.81)
6 BTBD9 37.82–38.79 rs9357271 38473851 T 0.82/0.76 6.7461027 2.01610216 7.75610222 1.47 (1.35–1.47)
9 PTPRD 8.80–8.88 rs1975197 8836955 A 0.19/0.16 4.9461025 1.0761026 3.49610210 1.29 (1.19–1.40)
15 MAP2K5/
SKOR1
65.25–65.94 rs12593813 65823906 G 0.75/0.68 1.4961026 1.54610217 1.37610222 1.41 (1.32–1.52)
New genome-wide significant loci (PJOINT , 5.2610
28)
2 intergenic
region
67.88–68.00 rs6747972 67923729 A 0.47/0.44 1.3761026 3.7361026 9.03610211 1.23 (1.16–1.31)
rs2116050 67926267 G 0.49/0.47 7.8461026 4.8561026 4.83610210 1.22 (1.15–1.30)
16 TOX3/
BC034767
51.07–51.21 rs3104767 51182239 G 0.65/0.58 7.3861027 2.16610213 9.40610219 1.35 (1.27–1.43)
rs3104788 51196004 T 0.65/0.58 1.1961026 2.42610213 1.63610218 1.33 (1.25–1.43)
RLS-associated SNPs with genome-wide significance. PGWA, l-corrected nominal P-value of GWA stage. PREPLICATION, nominal P-value obtained from meta-analysis of the
replication stage samples. PJOINT, nominal P-value of the joint meta-analysis of GWA and replication stage, l-corrected in samples where l-values were available.
Nominal P-values in GWA were calculated using logistic regression with sex, age, and the first four components from the MDS analysis of the IBS matrix as covariates.
For nominal PREPLICATION and PJOINT -values, a fixed-effects inverse-variance meta-analysis was performed. Risk allele frequencies and odds ratios were calculated in the
joint sample. LD blocks were defined by D’ using Haploview 4.2 based on HapMap CEU population data from HapMap release #27. CI, 95% confidence interval.
Genome positions refer to the Human March 2006 (hg18) assembly.
doi:10.1371/journal.pgen.1002171.t001
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been approved by the institutional review boards of the
contributing authors. The primary review board was located in
Munich, Bayerische A¨rztekammer and Technische Universita¨t
Mu¨nchen.
RLS patients (GWA and replication phase). A total of
2,944 cases (GWA =954, replication = 1,990) of European
descent were recruited in two cycles via specialized outpatient
clinics for RLS. German and Austrian cases for the GWA (GWA)
and the replication sample (GER1) were recruited in Munich,
Marburg, Kassel, Go¨ttingen, Berlin (Germany, n in GWA=830, n
in GER1=1,028), Vienna, and Innsbruck (Austria, n in
GWA=124, n in GER1=288). The additional replication
samples originated from Prag (Czech Republic (CZ), n = 351),
Montpellier (France (FR), n= 182), and Turku (Finland (FIN),
n = 141). In all patients, diagnosis was based upon the diagnostic
criteria of the International RLS Study Group [1] as assessed in a
personal interview conducted by an RLS expert. A positive family
history was based on the report of at least one additional family
member affected by RLS. We excluded patients with secondary
RLS due to uremia, dialysis, or anemia due to iron deficiency. The
presence of secondary RLS was determined by clinical interview,
physical and neurological examination, blood chemistry, and
nerve conduction studies whenever deemed clinically necessary.
In addition, 1,104 participants (GER2) of the ‘‘Course of RLS
(COR-) Study’’, a prospective cohort study on the natural course
of disease in members of the German RLS patient organizations,
were included as an additional replication sample. After providing
informed consent, study participants sent their blood for DNA
extraction to the Institute of Human Genetics, Munich, Germany.
A limited validation of the RLS diagnosis among the majority of
members was achieved through a diagnostic questionnaire. Five
percent had also received a standardized physical examination and
interview in one of the specialized RLS centers in Germany prior
to recruitment. To avoid doublets, we checked these subjects
against those recruited through other German RLS centers and
excluded samples with identical birth date and sex.
556 cases (US) were recruited in the United States at
Departments of Neurology at Universities in Baltimore, Miami,
Houston, and Palo Alto. Diagnosis of RLS was made as mentioned
above.
285 cases (CA) were recruited and diagnosed as above in
Montre´al, Canada. All subjects were exclusively of French-
Canadian ancestry as defined by having four grandparents of
French-Canadian origin.
Detailed demographic data of all samples are provided in Table
S6.
Control populations (GWA and replication phase). Controls
for German and Austrian cases were of European descent and
recruited from the KORA S3/F3 and S4 surveys, general population-
based controls from southern Germany. KORA procedures and
samples have been described [15]. For the GWA phase, we included
1,814 subjects from S3/F3, and, for the replication stage, 1,471
subjects from S4.
For replication of the GER2 sample, we used controls from the
Dortmund Health Study (DHS), a population-based survey
conducted in the city of Dortmund with the aim of determining
the prevalence of chronic diseases and their risk factors in the
general population. Sampling for the study was done randomly
from the city’s population register stratified by five-year age group
and gender [16]. 597 subjects selected at random from the Czech
blood and bone marrow donor registry served as Czech controls
[17]. French controls included 768 parents of multiple sclerosis
patients recruited from the French Group of Multiple Sclerosis
Genetics Study (REFGENSEP) [18]. Finnish controls comprised
360 participants of the National FINRISK Study, a cross-sectional
population survey on coronary risk factors collected every five
years. The current study contains individuals recruited in 2002.
Detailed description of the FINRISK cohorts can be found at
www.nationalbiobanks.fi.
French-Canadian controls were 285 unrelated individuals
recruited at the same hospital as the cases.
1,200 participants of the Wisconsin Sleep Cohort (WSC), an
ongoing longitudinal study on the causes, consequences, and
natural course of disease of sleep disorders, functioned as US
controls [19].
None of the controls were phenotyped for RLS. All studies were
approved by the institutional review boards in Germany, Austria,
Czech Republic, France, Finland, the US, and Canada. Written
informed consent was obtained from each participant. Detailed
demographic data of all samples are provided in Table S6.
Genotyping
GWA. Genotyping was performed on Affymetrix Genome-
Wide Human SNP Arrays 5.0 (cases) and 6.0 (controls) following
the manufacturer’s protocol. The case sample included 628 cases
from previous GWAs [2,4] and 326 new cases. After genotype-
calling using the BRLMM-P clustering algorithm [20], a total of
475,976 overlapping SNPs on both Affymetrix arrays were
subjected to quality control. We added 655 cases of a different
phenotype unrelated to RLS, genotyped on 5.0 arrays, to the
analysis and excluded those SNPs which showed a significant
difference of allele frequencies in cases (RLS and unrelated
phenotype on 5.0) and controls (6.0) (n = 92). Thereby, we filtered
out SNPs likely to be false-positive associations. We excluded SNPs
with a minor allele frequency (MAF) ,5% (n= 88,582), a callrate
,98% (n= 65,906) or a significant deviation from Hardy-
Weinberg Equilibrium (HWE) in controls (P,0.00001)
(n = 20,060). Cluster plots of the GWA genotyping data for the
best-associated SNPs in Table 1 are shown in Figure S5.
Genotypes of these SNPs are available in Table S7.
Replication. We selected all SNPs with a l-corrected
Pnominal,10
24 in the GWA for replication. These SNPs
clustered in 26 loci (defined as the best associated SNP 6150 kb
of flanking sequence). We genotyped a total of three SNPs in each
of the 26 regions. These were either further associated
neighbouring SNPs with a l-corrected Pnominal,10
23 or, in case
of singleton SNPs, additional neighbouring SNPs from HapMap
with the highest possible r2 (at least .0.5) with the best-associated
SNP. We also genotyped the best-associated SNPs identified in the
previous GWAs [2,4].
Genotyping was performed on the MassARRAY system using
MALDI-TOF mass spectrometry with the iPLEX Gold chemistry
(Sequenom Inc, San Diego, CA, USA). Primers were designed using
AssayDesign 3.1.2.2 with iPLEX Gold default parameters. Automat-
ed genotype calling was done with SpectroTYPER 3.4. Genotype
clustering was visually checked by an experienced evaluator.
Figure 2. Forest plots of the RLS risk loci (1 SNP per locus). OR and corresponding confidence interval for the GWA sample, all individual
replication samples, the combined replication sample as well as the combined GWA and replication sample are depicted. ORs are indicated by
squares with the size of the square corresponding to the sample size for the individual populations. (A) rs2300478 in MEIS1; (B) rs9357271 in BTBD9;
(C) rs1975197 in PTPRD; (D) rs12593813 in MAP2K5/SKOR1; (E) rs6747972 in intergenic region on chromosome 2; (F) rs3104767 in TOX3/BC034767.
doi:10.1371/journal.pgen.1002171.g002
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Figure 3. New genome-wide significant RLS loci. a) Risk locus on chromosome 2p14, showing the best-associated SNP rs6747972 and 6200 kb
of surrounding sequence. b) Risk locus on chromosome 16p21, showing the best-associated SNP rs3104767 and 6200 kb of surrounding sequence.
The left-hand x-axis shows the negative log10 of the nominal l-corrected P-values of the GWA stage for all SNPs genotyped in the respective region.
The right-hand x-axis shows the recombination frequency in cM/Mb. The y-axis shows the genomic position in Mb based on the hg18 assembly. The
r2-based LD between SNPs is colour-coded, ranging from red (r2.0.8) to dark blue (r2,0.2) and uses the best-associated SNP as reference. This SNP is
depicted as a violet diamond. Recombination frequency and r2 values are calculated from the HapMap II (release 22) CEU population. Plots were
generated with LocusZoom 1.1 (http://csg.sph.umich.edu/locuszoom/).
doi:10.1371/journal.pgen.1002171.g003
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SNPs with a call rate,95%, MAF,5%, and P,0.00001 for
deviations from HWE in controls were excluded. DNA samples
with a call rate,90% were also excluded.
Population stratification analysis
GWA. To identify and correct for population stratification, we
performed an MDS analysis as implemented in PLINK 1.07
(http://pngu.mgh.harvard.edu/,purcell/plink, [21]) on the IBS
matrix of our discovery sample. After excluding outliers by plotting
the main axes of variation against each other, we performed
logistic regression with age, sex, and the values of the MDS
components as covariates. Using the Genomic Control approach
[22], we obtained an inflation factor l of 1.11.
Additionally, we performed a variance components analysis
using the EMMAX software (http://genetics.cs.ucla.edu/emmax,
[23]) and, again, calculated the inflation factor with Genomic
Control, now resulting in a l of 1.025. EMMAX uses a mixed
linear model and does not only correct for population stratification
but also for hidden relatedness. We, therefore, decided to base
correction for population substructure on the EMMAX results.
Replication. Correction for population stratification was
performed for the German, Czech, and the Canadian
subsamples. The l-values of 1.1032, 1.2286, and 1.2637 were
derived from a previous Genomic Control experiment within the
same samples using 176 intergenic or intronic SNPs [4]. Here, we
had applied the expanded Genomic Control method GCF
developed by Devlin and Roeder [24]. In the meta-analysis of
all replication samples, the l-corrected standard errors were
included for the German, Czech, and Canadian samples. For the
other replication samples from France, Finland, and the USA, no
such data was available and, therefore, no correction factor was
included in the analysis.
Statistical analysis
Statistical analysis was performed using PLINK 1.07 (http://
pngu.mgh.harvard.edu/,purcell/plink, [21]). In the GWA sam-
ple, we applied logistic regression with age, sex, and the first four
axes of variation resulting from an MDS analysis as covariates.
P-values were l-corrected with the l of 1.025 from the EMMAX
analysis. In the individual analysis of the single replication samples,
we tested for association using logistic regression and correcting for
gender and age as well as for population stratification where possible
(see Population Stratification). Each replication sample was
Bonferroni-corrected using the number of SNPs which passed
quality control for the respective sample.
For the combined analysis of all replication samples, we
performed a fixed-effects inverse-variance meta-analysis. Where
available, we used l-corrected standard errors in this analysis.
Bonferroni-correction was performed for 74 SNPs, i.e. the number of
SNPs which passed quality control in at least one replication sample.
For the joint analysis of the GWA and the replication samples,
we also used a fixed-effects inverse-variance meta-analysis and
again included l-corrected values as far as possible. For the
conditioned analysis, the SNP to be conditioned on was included
as an additional covariate in the logistic regression analysis as
implemented in PLINK.
Interaction analysis was performed using the –epistasis option in
PLINK. Significance was determined via Bonferroni-correction
(i.e. 0.05/28, as 28 SNP combinations were tested for interaction).
Power calculation
Power calculation was performed using the CaTS power
calculator [25] using a prevalence set of 0.08 and an additive
genetic model (Table S3). The significance level was set at 0.05/74
for replication stage analysis and at 0.05/301,406 for genome-
wide significance in the joint analysis of GWA and replication. For
the rare variants association study, the significance level was set at
0.05/12.
Mutation screening of TOX3 and BC034767
All coding and non-coding exons including adjacent splice sites
of TOX3 (reference sequence NM_001146188) and BC034767
(reference sequence IMAGE 5172237) were screened for muta-
tions in 188 German RLS cases.
Mutation screening was performed with high resolution melting
curve analysis using the LightScanner technology and standard
protocols (IDAHO Technology Inc.). DNAs were analyzed in
doublets. Samples with aberrant melting pattern were sequenced
using BigDyeTerminator chemistry 3.1 (ABI) on an ABI 3730
sequencer. Sequence analysis was performed with the Staden
package [26]. Primers were designed using ExonPrimer (http://
ihg.gsf.de) or Primer3plus (www.bioinformatics.nl/cgi-bin/pri-
mer3plus/primer3plus.cgi). All identified variants were then
genotyped in 735 RLS cases and 735 controls of the general
population (KORA cohort) on the MassARRAY system, as
described above.
In addition, fragment analysis of exon 7 of TOX3 was performed
to screen for polymorphic CAG trinucleotide repeats. DNA of 100
controls (50 females, 50 males) was pooled and analyzed on an
ABI 3730 sequencer with LIZ-500 (ABI) as a standard. Primers
were designed using Primer3plus, the forward Primer contains
FAM for detection. Analysis was performed using GeneMapper
v3.5.
Expression analyses
Associations between MEIS1/ETAA1 RNA expression and
rs6747972 and between TOX3/BC034767/CREB-1/CREBBP/
CITED1 expression and rs3104767 were assessed using genome-
wide SNP data (Affymetrix 6.0 chip) in conjunction with
microarray data for human blood samples (n = 323 general
population controls from the KORA cohort, Illumina Human
WG6 v2 Expression BeadChip) [11]. A linear regression model
conditioned on expression and controlling for age and sex was
used to test for association.
Prediction of genetic risk
Based on the performance of P-value-threshold selected
SNPs in a training and a test sample. As training sample, we
used those GWA-cases which had also been genotyped for our
previous study [2]. We also included the control samples from this
study. As a first quality control step, we carried out an association
analysis comparing the Affymetrix 500K genotypes of these GWA-
cases to the Affymetrix 5.0 genotypes of the same cases. Significant
P-values would indicate systematic differences in the genotyping
between the different chips. For further analysis, we only used
those 259,302 SNPs with P-values .0.10. We performed a second
quality control step in which IDs with a callrate below 98% and
SNPs with a callrate below 98%, a MAF lower than 5%, or a P-
value for deviation from HWE,0.00001 were removed.
Further, we excluded the four already known risk loci as well as
the two newly identified loci and performed LD-pruning to limit
the analysis to SNPs not in LD with each other. This was
performed using a window-size of 50 SNPs. In each step, this
window was shifted 5 SNPs. We used a threshold of 2 for the VIF
(variance inflation factor). 76,532 SNPs, 326 cases, and 1,498
controls were included in the final training dataset. We conducted
logistic regression with age and sex as covariates. Based on these
association results, the sum score of SNPs showing the most
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significant effects (i.e. the number of risk alleles over all SNPs)
weighted by the ln(OR) of these effects was chosen as predictor
variable in the test set, comprising the remaining 583 cases of the
GWA sample and 1,526 controls. None of these cases/controls
were included in the training-sample, i.e. the test-sample
constitutes a completely independent sample. Based on this sum
score, we calculated the ROC curve and Nagelkerke’s R to
measure the explained variance.
Based on a weighted risk allele score. To evaluate the
predictive value in our sample, we calculated a weighted sum score
of risk alleles in the combined GWA and replication sample. To
this end, we used one SNP from each RLS risk region and also
included markers from the two newly identified regions on
chromosome 16q12 and 2p14 (MEIS1: rs2300478, 2p14:
rs6747972, BTBD9: rs9296249, PTPRD: rs1975197, MAP2K5:
rs11635424, TOX3/BC034767: rs3104767). At each SNP, the
number of risk alleles was weighted with the corresponding ln(OR)
for this SNP. The corresponding distribution of the score in cases
and controls is illustrated in Figure S3. Employing this score for
risk prediction resulted in an AUC of 0.651 (Figure S4).
Supporting Information
Figure S1 MDS analysis plot for GWA. Distribution of cases
(red) and controls (black) along the two main axes of variation
identified in the MDS analysis. The three visible clouds are due to
a common 3.8 Mb inversion polymorphism on chromosome 8
(described in: Tian C, Plenge RM, Ransom M, Lee A, Villoslada
P, et al. (2008) Analysis and Application of European Genetic
Substructure Using 300 K SNP Information. PLoS Genet 4: e4.
doi:10.1371/journal.pgen.0040004).
(TIFF)
Figure S2 QQ-plot of GWA results. QQ-plot showing the
P-value distribution before (red) and after (blue) correction for
population stratification using Genomic Control.
(TIFF)
Figure S3 Weighted risk allele score analysis. Histogram of the
weighted risk allele scores for cases and controls. The correspond-
ing OR and CI for each category against the median category is
depicted in green. The left y-axis refers to the number of
individuals (in %), the right-axis refers to the OR values.
(TIFF)
Figure S4 ROC curve for weighted risk score analysis. Receiver
operating characteristic (ROC) curve for the weighted risk allele
score approach of risk prediction. The area under the curve (AUC)
is 65.1%.
(TIFF)
Figure S5 Cluster plots of GWA genotyping for the six risk loci.
For the best-associated SNPs at each risk locus, clusterplots were
generated for cases and controls. Intensities of the A and B allele
(based on the Affymetrix annotation of the SNPs) are given on the
x- and y-axes and the respective genotypes are indicated in blue,
green, and orange.
(PDF)
Table S1 GWA results for SNPs with l-corrected PGWA,10–4
and additional SNPs selected for replication. A star (*) indicates
SNPs which had been identified in previous RLS GWAs [2–4].
P-values of the GWA phase are given as l-corrected nominal
P-values. Two different methods for l correction were applied,
multi-dimensional-scaling (MDS)-analysis using PLINK and
variance components (VC)-analysis using the EMMAX software
with the P-values listed in the respective columns ‘‘MDS
l-corrected PGWA’’ and ‘‘VC l-corrected PGWA’’. The selection
of SNPs for replication was based on the MDS l-corrected P-
values. r2-values based on Hapmap CEU data are given for those
SNPs which were selected for replication based on their LD with
the best-associated SNP in each region. Genomic position and
gene annotation refer to the hg18 genome.
(DOC)
Table S2 Replication stage association results for individual
replication samples. P-values are derived from logistic regres-
sion and correcting for gender and age as well as for
population stratification where possible (see Materials and
Methods). Each replication sample was Bonferroni-corrected
using the number of SNPs which passed quality control for the
respective sample. The OR refers to the minor allele. NA; SNP
could not be analysed due to failing quality control in the
respective sample.
(DOC)
Table S3 Power analysis for GWA, replication and joint analysis of
GWA and replication. Power calculation was performed using the
CaTS power calculator [25] using a prevalence set of 0.08 and an
additive genetic model. The significance level awas set at 0.05/74 for
replication stage analysis and at 0.05/301,406 for genome-wide
significance in the joint analysis of GWA and replication.
(DOC)
Table S4 Results of TOX3 and BC034767 mutation screening.
* ‘‘A’’ refers to the mutant allele, ‘‘B’’ to the reference allele.
Position refers to hg18 genome annotation. Codon numbering
refers to the reference sequence NM_001146188. Data of the 1000
genomes project was obtained from the November 2010 release
via the 1000 genomes browser (http://browser.1000genomes.org/
index.html).
(DOC)
Table S5 Prediction of genetic risk; training- and test-set
approach. Inclusion threshold P-values were derived from a
logistic regression with age and sex as covariates in the training
sample. # SNPs indicates the number of SNPs passing the
inclusion threshold. Based on these association results, the sum
score of SNPs showing the most significant effects (i.e. the number
of risk alleles over all SNPs) weighted by the ln(OR) of these effects
was chosen as predictor variable in the test set. Based on this sum
score, an AUC and Nagelkerke’s R were calculated.
(DOC)
Table S6 Demographic data of GWA and replication samples.
Mean age, mean age of onset and respective standard deviations
and ranges are given in years. N: number of individuals; SD:
standard deviation; AAO: age of onset. GWA: Genome-wide
association study; CZ: Czechia; FR: France; FIN: Finland; CA:
Canada; US: United States. - indicates that this information is not
applicable for the respective sample.
(DOC)
Table S7 Genotype data of GWA samples. Genotypes of the
GWA samples are given for the eight best-associated SNPs (see
Table 1). SNP alleles are ACGT-coded. Phenotype information
includes gender (1 = male, 2 = female) and disease status (1 =
unaffected, 2 = affected).
(XLS)
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